{"id":"tirosint-sol","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Heat intolerance"},{"rate":null,"effect":"Weight loss"}]},"_chembl":null,"_dailymed":{"setId":"5d378add-f13d-40f2-99dc-0f2340ab44b7","title":"TIROSINT SOL (LEVOTHYROXINE SODIUM) SOLUTION [IBSA PHARMA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levothyroxine is a synthetic form of thyroxine (T4), a thyroid hormone that is converted peripherally to the active T3 form. It binds to thyroid hormone receptors throughout the body to regulate metabolism, energy production, and growth. The liquid formulation (SOL) provides improved bioavailability and more consistent absorption compared to tablet formulations, particularly in patients with malabsorption issues or those taking concurrent medications that interfere with absorption.","oneSentence":"Tirosint-SOL is a liquid formulation of levothyroxine that replaces deficient thyroid hormone to restore normal thyroid function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:51.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypothyroidism (replacement therapy)"},{"name":"Thyroid cancer suppression therapy"},{"name":"Myxedema coma"}]},"trialDetails":[{"nctId":"NCT05228184","phase":"PHASE4","title":"Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)","status":"TERMINATED","sponsor":"IBSA Institut Biochimique SA","startDate":"2022-01-21","conditions":"Congenital Hypothyroidism","enrollment":34},{"nctId":"NCT04747275","phase":"PHASE4","title":"Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients","status":"TERMINATED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2021-01-18","conditions":"Hypothyroidism, Trisomy 21","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["levothyroxine sodium oral solution (liquid)"],"phase":"marketed","status":"active","brandName":"Tirosint®-SOL","genericName":"Tirosint®-SOL","companyName":"IBSA Institut Biochimique SA","companyId":"ibsa-institut-biochimique-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tirosint-SOL is a liquid formulation of levothyroxine that replaces deficient thyroid hormone to restore normal thyroid function. Used for Hypothyroidism (replacement therapy), Thyroid cancer suppression therapy, Myxedema coma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}